Zobrazeno 1 - 10
of 36
pro vyhledávání: '"S. Kanatakis"'
Autor:
S. Kanatakis, I. Ketikoglou, D. Tsantoulas, G. Anagnostopoulos, M. Raptopoulou, Vana Sypsa, G. Hatzis, I. Vafiadis, L. Sidiropoulos, N. C. Tassopoulos, Angelos Hatzakis
Publikováno v:
Journal of Viral Hepatitis. 10:383-389
Summary. A randomized trial was conducted to assess the efficacy of interferon-alpha (IFN) daily in combination with ribavirin in 301 naive patients with chronic hepatitis C (CHC). Patients were randomized to receive ribavirin 1.2 g daily (QD) for 48
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::001b7f50188b2bca8de3daa27824d505
https://doi.org/10.1046/j.1365-2893.2003.00439.x
https://doi.org/10.1046/j.1365-2893.2003.00439.x
Autor:
O, Anagnostou, S, Manolakopoulos, G, Bakoyannis, G, Papatheodoridis, A, Zisouli, M, Raptopoulou-Gigi, E, Manesis, I, Ketikoglou, G, Dalekos, C, Gogos, T, Vassiliadis, D, Tzourmakliotis, S, Karatapanis, S, Kanatakis, Zoumpoulis, A, Hounta, S, Koutsounas, G, Giannoulis, N, Tassopoulos, G, Touloumi
Publikováno v:
Hippokratia. 18(1)
Patients with genotype 4 (G4) chronic hepatitis C (CHC) are considered a difficult to treat population, although current data on G4 treatment responsiveness and duration are controversial. Greece represents a country with an intermediate prevalence o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8e5396969494668b7f2863cae3144a5f
https://pubmed.ncbi.nlm.nih.gov/25125954
https://pubmed.ncbi.nlm.nih.gov/25125954
Autor:
Anastasia Karafoulidou, S. Koutsounas, George Kitis, S. Kanatakis, E.K. Manesis, Giota Touloumi, A. Antoniou, I. Vafiadis, George V. Papatheodoridis, J. Ketikoglou
Publikováno v:
Alimentary pharmacologytherapeutics. 29(10)
Interferon (IFN-alpha)-based regimens have been used with varying success in the treatment of chronic hepatitis C (CHC) for over two decades. The effect of such treatments on the natural course of CHC has been evaluated in small clinical trials with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01fdfba116dacbf7e9eb5838d0ae5764
https://pubmed.ncbi.nlm.nih.gov/19222410
https://pubmed.ncbi.nlm.nih.gov/19222410
Autor:
Themistoklis Vassiliadis, G. Hatzis, I. Ketikoglou, D. Tsantoulas, M. Raptopoulou, I. Vafiadi, Evangelos Akriviadis, S. Kanatakis, E. Paraskevas, L. Sidiropoulos
Publikováno v:
Journal of viral hepatitis. 12(1)
The aim was to demonstrate adherence to treatment has been suggested to enhance rates of sustained response in patients with hepatitis C. In this study, we evaluated the effect of drug dosage reduction or the duration of the expected therapy in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::972b89f0e480b1edfd445c8af302482e
https://pubmed.ncbi.nlm.nih.gov/15655054
https://pubmed.ncbi.nlm.nih.gov/15655054
Autor:
N. C Tassopoulos, D. Tsantoulas, M. Raptopoulou, T. Vassiliadis, S. Kanatakis, E. Paraskevas, I. Vafiadis, A. Avgerinos, C. Tzathas, S. Manolakopoulos, I. Ketikoglou, P. Aggelis, K. Goritsas, G. Giannoulis, G. Hatzis G, K. Thomopoulos, E. Akriviadis, V. Sypsa, A. Hatzakis
Publikováno v:
Journal of viral hepatitis. 10(3)
SUMMARY. A randomized trial was conducted to assess the efficacy of daily (QD) or thrice weekly (TIW) administration of interferon-a (IFN) in high doses in combination with ribavirin (1.0‐1.2 g/day) in patients with chronic hepatitis C (CHC) who we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::491364f2f71fa26cd86677bd8ca30b91
https://pubmed.ncbi.nlm.nih.gov/12753337
https://pubmed.ncbi.nlm.nih.gov/12753337
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of hepatology. 10(3)
The antibody response to hepatitis B surface antigen (anti-HBs) was studied in 15 chronic hepatitis B virus (HBV)-infected patients who seroconverted following treatment with alpha interferon. The levels of anti-HBs (IU/l) attained were significantly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc8171b71892b56447b5fa0595330cd1
https://pubmed.ncbi.nlm.nih.gov/2142176
https://pubmed.ncbi.nlm.nih.gov/2142176
Publikováno v:
Journal of Hepatology. 28:208
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccb3c895e3b18b411ac6fb7c6d2bdcd1
https://doi.org/10.1016/s0168-8278(98)81009-x
https://doi.org/10.1016/s0168-8278(98)81009-x
Publikováno v:
Journal of Hepatology. 28:203
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4289c39ce83dbb126d320d41effe4178
https://doi.org/10.1016/s0168-8278(98)80989-6
https://doi.org/10.1016/s0168-8278(98)80989-6
Autor:
Michael J. McGarvey, J.A. McDonald, L. J. Scully, S. Kanatakis, Andrew Lever, Peter Karayiannis, G. Chen, Howard C. Thomas
Publikováno v:
Scopus-Elsevier
Response to interferon therapy in chronic hepatitis B virus (HBV) carriers is preceded by the appearance of IgM class anti-HBc (antibody to hepatitis B core antigen). The temporal relationship and magnitude of the IgM anti-HBc response is variable su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea2302475e2605646270bf4acf6604ab
https://pubmed.ncbi.nlm.nih.gov/2767509
https://pubmed.ncbi.nlm.nih.gov/2767509